Among patients with obesity, GLP-1 RAs were associated with a lower hazard of all-cause mortality and recurrence-free survival over a 10-year follow-up period. (HealthDay News) — Glucagon-like peptide ...

Patients have reportedly experienced classic Ebola disease symptoms like fever, headache, vomiting, severe weakness, abdominal pain, nosebleeds and vomiting blood, the CDC said.

Supported by phase 3 trial data showing significant SARA score improvements, levacetylleucine is on track to potentially become the first approved therapy for A-T.

Decrease seen in annualized asthma exacerbation rate overall and across asthma phenotypes and underrepresented populations ...

In the phase 3 OCEANIC-STROKE trial, asundexian significantly reduced recurrent ischemic stroke risk compared with placebo without significantly increasing major bleeding. The Food and Drug ...

Pediatricians should emphasize multiple layers of drowning prevention; barriers limiting their use should be examined ...

Credit: AstraZeneca. Baxfendy offers novel mechanism of action for patients whose blood pressure remains uncontrolled despite background antihypertensive therapy. According to AstraZeneca, Baxfendy is ...

The TROP2-directed antibody-drug conjugate demonstrated superior efficacy over physician’s choice of chemotherapy in patients previously treated with platinum-based therapy and immunotherapy.

Two interchangeable golimumab biosimilars were approved for the treatment of rheumatoid arthritis and ulcerative colitis.

Modest but statistically significant reduction seen for women with placenta previa undergoing cesarean delivery.

A Prescription Drug User Fee Act target date of December 27, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR ...

Enhertu was approved for both neoadjuvant and adjuvant treatment in patients with HER2-positive early breast cancer. The Food and Drug Administration (FDA) has expanded the approval of Enhertu ® ...